drugset
drugset / Trial / NCT02585440

A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects

NCT02585440 ↗

Phase 1 Completed 50 enrolled ContraVir Pharmaceuticals, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a phase 1 study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.

Timeline

Start
2016-04
Primary completion
2016-08
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir Exalidex Other / unclassified 5 mg Oral
Subject Tenofovir Exalidex Other / unclassified 10 mg Oral
Subject Tenofovir Exalidex Other / unclassified 25 mg Oral
Subject Tenofovir Exalidex Other / unclassified 50 mg Oral
Subject Tenofovir Exalidex Other / unclassified 100 mg Oral

Indications

infectious disease